0.7504USD-3.78%Mkt Cap: 7.94M USDP/E: —Last update: 2026-06-01
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new the…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap7.94M USD
Enterprise Value-9.80M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-16.23M USD
Revenue/Share—
Last Price0.7504 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees13
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS3724461047
Valuation
P/E (Trailing)—
P/E (Forward)-0.36
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.32
EPS (TTM)-5.06
EPS (Forward)-2.18
52W Range
0.72230% of range55.00
52W High55.00 USD
52W Low0.7223 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-203.83%
ROA-159.75%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.31M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-114.50%
Net Debt-18.05M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio5.61
Quick Ratio5.38
Book Value/Sh2.419 USD
Cash/Share1.705 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateOct 21, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.10.59M
Float10.56M
Insiders0.97%
Institutions1.01%
Short Interest
Short Ratio0.9d
Short % Float9.80%
Short % Out.9.77%
Shares Short1.03M
Short (prev mo.)505.52K
Technical
SMA 501.196 (-37.2%)
SMA 2004.688 (-84.0%)
Beta-0.93
S&P 52W Chg27.94%
Avg Vol (30d)917.71K
Avg Vol (10d)250.27K
Technical Indicators
RSI (14)30.8
MACD-0.1035
MACD Signal-0.1255
MACD Hist.+0.0220
BB Upper0.9313 USD
BB Middle0.8375 USD
BB Lower0.7437 USD
BB Width22.40%
ATR (14)0.0626 USD
Vol Ratio (20d)0.59x